Ending severe suffering is a desirable goal for both ethical and scientific reasons. The RSPCA has pledged to work toward the end of such suffering for laboratory animals, and in this article we outline a practical approach that establishments can follow to achieve this aim
Get full access to this article
View all access options for this article.
References
1.
Anon. (2010). Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. Official Journal of the European UnionL276, 20.10.2010, 33–79.
2.
Home Office (2014). Guidance on the Operation of the Animals (Scientific Procedures) Act 1986, 164 pp. London, UK: The Stationery Office.
3.
Smith, J., van den Broek, F., Martorell, J., Hackbarth, H., Ruksenas, O. & Zeller, W.; FELASA Working Group on Ethical Evaluation of Animal Experiments (2007). Principles and practice in ethical review of animal experiments across Europe: Summary of the report of a FELASA working group on ethical evaluation of animal experiments. Laboratory Animals41, 143–160.
4.
FrancoN. & OlssonA. (2013). Is the ethical appraisal of protocols enough to ensure best practice in animal research. ATLA41, P5–P7.
5.
HunterJ. (2011). Have animal models of disease helped or hindered the drug discovery process? Annals of the New York Academy of Sciences1245, 1–2.
6.
FishmanM. (2013). Power of rare diseases: Found in translation. Science Translational Medicine5, 1–3.
7.
LandisS.C., AmaraS.G., AsadullahK., AustinC.P., BlumensteinR., BradleyE.W., CrystalR.G., DarnellR.B., FerranteR.J., FillitH., FinkelsteinR., FisherM., GendelmanH.E., GolubR.M., GoudreauJ.L., GrossR.A., GubitzA.K., HesterleeS.E., HowellsD.W., HuguenardJ., KelnerK., KoroshetzW., KraincD., LazicS.E., LevineM.S., MacleodM.R., McCallJ.M., MoxleyR.T., 3rd, NarasimhanK., NobleL.J., PerrinS., PorterJ.D., StewardO., UngerE., UtzU. & SilberbergS.D. (2012). A call for transparent reporting to optimize the predictive value of preclinical research. Nature, London490, 187–191.
8.
IoannidisJ., GreenlandS., HlatkyM., KhouryM., MacleodM., MoherD., SchulzK. & TibshiraniR. (2014). Increasing value and reducing waste in research design, conduct, and analysis. Lancet383, 166–175.
9.
HackamD. (2007). Translating animal research into clinical benefit. BMJ334, 163–164.
10.
LevinL.A. & Danesh-MeyerH.V. (2010). Lost in translation: Bumps in the road between bench and bedside. JAMA303, 1533–1534.
11.
IoannidisJ. (2012). Extrapolating from animals to humans. Science Translational Medicine151, 151–154.
12.
McGonigleP. & RuggeriB. (2014). Animal models of human disease: Challenges in enabling translation. Biochemical Pharmacology87, 162–171.
13.
PetersenY., BjörkenbergB., ChristjansenK., StahlhutM., PedersenH. & ThorkildsenC. (2009). Is the murine dextran sodium sulfate-induced colitis model valid for predicting drug efficacy in IBD?Gastroenterology136, Suppl. 1, A48.
14.
JenningsM., MortonD., ChartonE., CooperJ., HendriksenC., MartinS., PearceM.C., PriceS., RedheadK., ReedN., SimmonsH., SpencerS. & WillingaleH. (2010). Application of the Three Rs to challenge assays used in vaccine testing: Tenth report of the BVAAWF/FRAME/RSPCA/UFAW Joint Working Group on Refinement. Biologicals38, 684–695.
15.
AshallV. & MillarK. (2013). An opportunity to focus on the ‘humane’ in experimental endpoints: Moving beyond Directive 2010/63/EU. ATLA41, 307–312.
16.
LilleyE. & JenningsM. (2013). Refinement: Lessons from the 2012 Olympics. ATLA41, P28–P29.
17.
HawkinsP., MortonD., BurmanO., DennisonN., HonessP., JenningsM., LaneS., MiddletonV., RoughanJ., WellsS. & WestwoodK. (2011). A guide to defining and implementing protocols for the welfare assessment of laboratory animals. Laboratory Animals45, 1–13.
